The Current Ratio as of November 2024 (TTM) for TScan Therapeutics, Inc. (TCRX) is 9.56

According to TScan Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 9.56. This represents a change of 31.57% compared to the average of 7.27 of the last 4 quarters.

TScan Therapeutics, Inc. (TCRX) Historical Current Ratio (quarterly & annually)

How has TCRX Current Ratio performed in the past?

The mean historical Current Ratio of TScan Therapeutics, Inc. over the last ten years is 8.20. The current 9.56 Current Ratio has changed 11.57% with respect to the historical average. Over the past ten years (40 quarters), TCRX's Current Ratio was at its highest in in the September 2024 quarter at 9.56. The Current Ratio was at its lowest in in the June 2020 quarter at 0.

TScan Therapeutics, Inc. (TCRX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of TScan Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

TScan Therapeutics, Inc. (TCRX) Average Current Ratio

How has TCRX Current Ratio performed in the past?

The current Current Ratio of TScan Therapeutics, Inc. (TCRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

TScan Therapeutics, Inc. (TCRX) Current Ratio vs. Peers

How is TCRX’s Current Ratio compared to its peers?

TScan Therapeutics, Inc.’s Current Ratio is greater than VectivBio Holding AG (9.14), less than Icosavax, Inc. (18.06), greater than Apellis Pharmaceuticals, Inc. (4.36), less than iTeos Therapeutics, Inc. (14.80), less than Day One Biopharmaceuticals, Inc. (14.62), less than Acumen Pharmaceuticals, Inc. (10.43), greater than X4 Pharmaceuticals, Inc. (4.89), greater than Inozyme Pharma, Inc. (7.68), greater than Cognition Therapeutics, Inc. (2.11), greater than TFF Pharmaceuticals, Inc. (0.89), greater than Cue Biopharma, Inc. (2.22), greater than Dermata Therapeutics, Inc. (7.11), greater than ProQR Therapeutics N.V. (2.33), less than Annexon, Inc. (17.18), greater than Arrowhead Pharmaceuticals, Inc. (4.65), less than Terns Pharmaceuticals, Inc. (32.99),

Build a custom stock screener for TScan Therapeutics, Inc. (TCRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TScan Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

TScan Therapeutics, Inc. (TCRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like TScan Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.